+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study



A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study



Pediatric Blood and Cancer 61(3): 442-445



The prognosis for patients with nonpulmonary metastatic Ewing sarcoma remains poor with survival in the order of 15-20%. The need to introduce effective new agents into clinical practice is clear. Based on a preclinical rationale of responses in xenografts and backed by a phase I study in children, the Euro-E.W.I.N.G consortium planned a phase II window study of irinotecan in newly diagnosed high risk metastatic patients with Ewing sarcoma. Patients were recruited between April 2004 and December 2007. Two courses of irinotecan were administered at a dose of 600 mg/m(2) as a 1 hour infusion at 21 day intervals. Response evaluation was determined after the second course of treatment by radiological assessment of primary and metastatic sites and, where appropriate bone marrow sampling. Twenty-three patients were recruited. Two patients were deemed inevaluable for response. Five patients (24%) demonstrated a partial response. Grade 3 or 4 diarrhoea was seen in 4/43 course of treatment and was managed with loperamide. This is the first report of single agent irinotecan activity in an untreated population of patients with Ewing sarcoma. In common with other paediatric tumours and other camptothecin analogues such as topotecan, single agent activity is only modest. The exact role for the use of irinotecan in patients with ES, dose schedule and combinations with other agents still requires further investigation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051208940

Download citation: RISBibTeXText

PMID: 24019263

DOI: 10.1002/pbc.24767


Related references

Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. European Journal of Cancer 61: 128-136, 2016

Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). Bmj Open 6(1): E009558, 2016

A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. Bmc Cancer 14: 622, 2014

Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 17(3): 321-321, 2012

Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. Journal of Clinical Oncology 28(20): 3284-3291, 2010

Local control in Ewing sarcoma of the chest wall: results of the EURO-EWING 99 trial. Annals of Surgical Oncology 22(9): 2853-2859, 2015

Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-Oncology 4(2): 102-108, 2002

High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study. Pediatric Hematology and Oncology 27(4): 272-282, 2010

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet. Oncology 11(2): 129-135, 2010

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Investigational new Drugs 30(4): 1660-1670, 2012

The role of radiation therapy in the management of non-metastatic Ewing's sarcoma of bone. Report of the Intergroup Ewing's Sarcoma Study. International Journal of Radiation Oncology Biology Physics 7(2): 141-149, 1981

Ewing's sarcoma and primitive neuroectodermal tumor of hand and forearm. Experience of the Cooperative Ewing's Sarcoma Study Group. Journal of Cancer Research and Clinical Oncology 131(4): 219-225, 2005

Intramyofiber skeletal muscle invasion in Ewing's sarcoma of bone: clinicopathologic observations from the intergroup Ewing's sarcoma study. American Journal of Pediatric Hematology/Oncology 4(2): 231-235, 1982

Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. Pediatric Blood and Cancer 62(10): 1747-1753, 2015